Premium
Effect of alteration of caveolin‐1 expression on doxorubicin‐induced apoptosis in H9c2 cardiac cells
Author(s) -
Takaguri Akira,
Kamato Maiko,
Satoh Yoshiaki,
Ohtsuki Kazuaki,
Satoh Kumi
Publication year - 2015
Publication title -
cell biology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.932
H-Index - 77
eISSN - 1095-8355
pISSN - 1065-6995
DOI - 10.1002/cbin.10478
Subject(s) - doxorubicin , apoptosis , gene knockdown , caveolin 1 , cancer research , mapk/erk pathway , biology , microbiology and biotechnology , kinase , chemistry , biochemistry , chemotherapy , genetics
Doxorubicin is an anthracycline antibiotic widely used in cancer treatment. Although its antitumor efficacy appears to be dose dependent, its clinical use is greatly restricted by the development of cardiotoxicity associated with apoptosis. Although caveolin‐1, the major structural protein in caveolae, can positively or negatively regulate apoptosis depending on the stimulus or cell types, the contribution of caveolin‐1 to doxorubicin‐induced apoptosis remains unknown. This study was performed to identify the regulatory role of caveolin‐1 on doxorubicin‐induced apoptosis in H9c2 cardiac cells using a genetic approach. Caveolin‐1 knockdown with a short hairpin (sh) RNA adenovirus, but not overexpression of wild‐type caveolin‐1, resulted in a marked inhibition of doxorubicin‐induced caspase‐3 cleavage. However, caveolin‐1 knockdown tended to protect against doxorubicin‐induced decrease in cell viability, but it did not significantly reverse cell death induced by doxorubicin. Doxorubicin stimulated the phosphorylation of p38 and extracellular signal regulated kinase (ERK). Doxorubicin‐induced caspase‐3 cleavage was inhibited by U0126, a MEK inhibitor or SB203580, a p38 inhibitor. Caveolin‐1 knockdown markedly inhibited doxorubicin‐induced p‐38 phosphorylation but not ERK‐mediated p‐53 phosphorylation in H9c2 cardiac cells. Our results suggest that reduced caveolin‐1 expression plays an anti‐apoptotic role in doxorubicin‐induced apoptosis but that it is insufficient to prevent such an apoptosis in H9c2 cardiac cells.